Local Biotech Company Goes Public
Epizyme Inc, a Cambridge-based cancer drug company, commenced public trading last Friday. The biotech listed its initial public offering at $15 a share on the Nasdaq, under the ticker symbol “EPZM.” The rapidly-growing oncology company is offering 5.1 million shares, with the IPO expected to raise $88.8 million if all shares are sold. While only […]